# Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis

Study · id `cardio:ct-nct07539259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07539259](<https://clinicaltrials.gov/study/NCT07539259>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07539259

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 445 participants.

## Technical summary

Registry record NCT07539259. Randomized; no masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 445 participants (planned count; ClinicalTrials.gov record NCT07539259, source copy `cardio:ctgov-nct07539259-2026-09-11`, retrieved 2026-10-26)
- Planned start: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07539259, source copy `cardio:ctgov-nct07539259-2026-09-11`, retrieved 2026-10-26)
- Primary completion: 2029-08 (anticipated) (ClinicalTrials.gov record NCT07539259, source copy `cardio:ctgov-nct07539259-2026-09-11`, retrieved 2026-10-26)
- Completion: 2030-02-28 (anticipated) (ClinicalTrials.gov record NCT07539259, source copy `cardio:ctgov-nct07539259-2026-09-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07539259-2026-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
- Acronym: RELIEF-AS
- Condition: Aortic Stenosis
- Intervention (Drug): Dapagliflozin (DAPA)
- Intervention (Drug): Spironolactone (drug)
- Intervention (Drug): Spironolactone + Dapagliflozin
- Intervention (Drug): Epleronone
- Lead sponsor: University College, London
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: University College, London (`cardio:org-university-college-london`)

## Provenance

Content hash: 637e3494fbca3c8a865c21dd0a6e88dec09c24195aa405e1d0be30cadb110a01
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
